Skip to Content

Join the 'Lymphoma' group to help and get support from people like you.

Lymphoma News

Related terms: Cancer, Lymphoma

FDA Medwatch Alert: Breast Implants: Update - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Posted 21 Mar 2017 by Drugs.com

ISSUE: FDA has updated its understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) to reflect the agency’s concurrence with the World Health Organization designation of BIA-ALCL as a rare T-cell lymphoma that can develop following breast implants. At this time, most data suggest that BIA-ALCL occurs more frequently following implantation of breast implants with textured surfaces rather than those with smooth surfaces. BIA-ALCL is a rare condition; when it occurs, it has been identified most frequently in patients undergoing implant revision operations for late onset, persistent seroma. The exact number of cases remains difficult to determine due to significant limitations in world-wide reporting and lack of global implant sales data. See the FDA Update for additional information, including a summary of Medical Device Reports and medical literature, and r ... Read more

Related support groups: Lymphoma

FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)

Posted 15 Mar 2017 by Drugs.com

KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy. Under the FDA’s accelerated approval regulations, this indication is approved based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. In refractory or relapsed cHL, Keytruda is approved for use in adult patients at a fixed dose of 200 mg and in pediatric patients at a dose of 2 mg/kg (up to a maximum of 200 ... Read more

Related support groups: Lymphoma, Keytruda, Hodgkin's Lymphoma, Pembrolizumab

Gene Therapy Shows Promise for Aggressive Lymphoma

Posted 28 Feb 2017 by Drugs.com

TUESDAY, Feb. 28, 2017 – An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report. Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif. These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release. Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said. "This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press. But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma

U.S. FDA Approves Imbruvica (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Posted 25 Jan 2017 by Drugs.com

NORTH CHICAGO, Ill., Jan. 19, 2017 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 This indication is approved under accelerated approval based on overall response rate (ORR), and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. Imbruvica is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. "The FDA approval of Imbruvica for relapsed/refractory marginal zone lymphoma is significant, and we are proud of the culmination of this extensive clinical research program, representing ... Read more

Related support groups: Lymphoma, Imbruvica, Ibrutinib

Worldwide Cancer Rates Up More Than One-Third in Past Decade: Report

Posted 4 Dec 2016 by Drugs.com

SATURDAY, Dec. 3, 2016 – Cancer cases rose 33 percent worldwide in the past 10 years, a new study shows. In 2015, there were 17.5 million diagnoses and 8.7 million deaths in the world from the disease, the researchers found. The rise in cancer cases was mainly due to population aging and growth, along with changes in age-specific cancer rates, according to the Global Burden of Disease Cancer Collaboration study. The lifetime risk of developing cancer was one in three for men and one in four for women, the researchers said. Prostate cancer was the most common type of cancer in men (1.6 million cases), and tracheal, bronchus and lung cancer was the leading cause of cancer death in men. Breast cancer was the most common cancer for women (2.4 million cases), and the leading cause of cancer death in women. The most common cancers in children were leukemia, other neoplasms, non-Hodgkin ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Melanoma, Skin Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Cancer, Testicular Cancer, Salivary Gland Cancer, Solid Tumors

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Burkitt Lymphoma, Diagnosis and Investigation, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Stem Cell Transplant Can Help HIV Patients Battling Lymphoma: Study

Posted 15 Jun 2016 by Drugs.com

WEDNESDAY, June 15, 2016 – People living with HIV are at high risk for lymphoma, and a new study concludes that stem cell transplant should be standard treatment in these cases. The transplants should be "autologous" – meaning the cells come from the patients themselves, the researchers said. The new findings could challenge the widely held belief that HIV-positive patients are not candidates for this therapy. Instead, the study found that "overall survival for patients with HIV infection after transplant is comparable to that seen in people who were not HIV-infected," said study lead author Dr. Joseph Alvarnas. As his team explained, people with HIV are at increased risk for cancer, even if their infection is well-controlled with antiretroviral drugs. In fact, cancer is now a leading cause of death among HIV patients. The risk of non-Hodgkin lymphoma, specifically in HIV-positive ... Read more

Related support groups: HIV Infection, Lymphoma, Non-Hodgkin's Lymphoma

Radon in the Home May Be Linked to Blood Cancers in Women

Posted 3 May 2016 by Drugs.com

TUESDAY, May 3, 2016 – New research suggests a strong link between exposure to high levels of radon in the home and women's risk of blood cancers. Radon is a naturally occurring radioactive gas, the U.S. Environmental Protection Agency says. It's known to cause lung cancer and is the second leading cause of lung cancer in the United States, the researchers said. The American Cancer Society collected information over 19 years on more than 140,000 Americans as part of a prevention study. During that time, just over 3,000 cases of blood cancer were diagnosed. The cancers included leukemia, lymphoma and myeloma, the study found. Women who lived in counties with the highest radon levels were 63 percent more likely to develop blood cancers than those in counties with the lowest radon levels. There was no link seen among men, the study noted. The study was published online recently in the ... Read more

Related support groups: Cancer, Leukemia, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma, Multiple Myeloma, Poisoning, Small Cell Lung Cancer, Toxic Reactions Incl Drug and Substance Abuse

Male Childhood Cancer Survivors Less Likely to Have Kids, Study Finds

Posted 24 Feb 2016 by Drugs.com

WEDNESDAY, Feb. 24, 2016 – Men who survived cancer when they were children, teens or young adults seem to be less likely to have children of their own than men who never had cancer, a new study reveals. The likelihood of having children was especially low among those who survived testicular cancer, bone cancer, brain tumors, lymphoma and leukemia, researchers at the University of Bergen in Norway found. The findings "are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction problems," study author Maria Winther Gunnes, a Ph.D. candidate in the department of global public health and primary care, said in a university news release. For the study, researchers reviewed data from all Norwegian men born between 1965 and 1985. Male cancer survivors were three times more likely to use assisted fertilization than those who never had cancer, the ... Read more

Related support groups: Cancer, Female Infertility, Leukemia, Lymphoma, Brain Tumor, Oligospermia, Testicular Cancer

Could IVF Raise Children's Odds for Blood Cancer?

Posted 4 Feb 2016 by Drugs.com

THURSDAY, Feb. 4, 2016 – Children conceived through in vitro fertilization (IVF) might have a slightly increased risk of developing blood cancer, a new study suggests. Children born via IVF had a 67 percent increased risk of leukemia and a more than tripled risk of Hodgkin's lymphoma compared to children conceived naturally, researchers found in an analysis of more than 1.6 million children in Norway. Parents shouldn't panic, however. The risk of childhood cancer is still very small, even after factoring in the results of this study, said lead author Dr. Marte Myhre Reigstad. She is a researcher with the Norwegian National Advisory Unit on Women's Health at Oslo University Hospital. "For example, in Norway, the risk of being diagnosed with leukemia within the first 10 years of life is 0.5 in 1,000," Reigstad said. "A risk increase of such magnitude as found in our study would amount to ... Read more

Related support groups: Female Infertility, Leukemia, Lymphoma, Ovulation Induction, Primary Ovarian Failure, Follicle Stimulation

Lymphoma Survivors May Not Get All Recommended Follow-Up Care

Posted 15 Jan 2016 by Drugs.com

FRIDAY, Jan. 15, 2016 – Some teen and young adult survivors of Hodgkin lymphoma do not receive all the recommended follow-up care, a new study finds. The study included 354 survivors in California who were diagnosed between ages 15 and 39, and followed for an average of six years. Within the first year, 52 percent of the survivors did not receive all recommended care outlined in the National Comprehensive Cancer Network guidelines. But within five years after completing treatment, 96 percent of the survivors had recommended visits (at least one a year) with an oncologist and 70 percent had recommended laboratory testing, according the study authors. The study is scheduled for presentation Friday at an American Society of Clinical Oncology (ASCO) meeting in San Francisco. The findings should be viewed as preliminary until published in a peer-reviewed journal. Hodgkin lymphoma, a cancer ... Read more

Related support groups: Lymphoma, Hodgkin's Lymphoma

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Basal Cell Carcinoma, Lymphoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Testicular Cancer, Acute Lymphocytic Leukemia

Kids Born to Older Dads May Face Risk of Blood Cancers

Posted 12 May 2015 by Drugs.com

TUESDAY, May 12, 2015 – Adults who were born to older fathers may be at increased risk for blood and immune system cancers such as leukemia and lymphoma, a new study suggests. This association is particularly strong among only children, the American Cancer Society investigators added. However, the study did not prove there was a cause-and-effect link between the two. There was no association between having an older mother and increased risk of these cancers, according to the study published online May 11 in the American Journal of Epidemiology. "The lifetime risk of these cancers is fairly low – about one in 20 men and women will be diagnosed with lymphoma, leukemia or myeloma at some point during their lifetime – so people born to older fathers should not be alarmed," study leader Lauren Teras said in a journal news release. "Still, the study does highlight the need for more ... Read more

Related support groups: Leukemia, Lymphoma, Multiple Myeloma

Screening Test Approved for Viruses That Cause Blood Cancer

Posted 11 Dec 2014 by Drugs.com

THURSDAY, Dec. 11, 2014 – A new screening test to detect Human T-Cell Lymphotropic viruses that cause a rare blood cancer has been approved by the U.S. Food and Drug Administration. The viruses, abbreviated HTLV-I/II, cause diseases such as adult T-cell leukemia/lymphoma (blood cancer) and myelopathy (inflammation of spinal cord nerves) , the FDA said in a news release. HTLV can be transmitted via breastfeeding, unprotected sex or blood transfusion. The newly approved test – MP Diagnostics HTLV Blot 2.4 – is meant to supplement existing screening for the viruses, the FDA said. The diagnostic also can differentiate between the two types, HTLV-I or HTLV-II. Many people infected with HTLV may not be aware of its presence, since the virus does not always trigger symptoms. An infected person can transmit the virus without showing any signs or symptoms, the agency said. The new test is ... Read more

Related support groups: Leukemia, Lymphoma, Diagnosis and Investigation

Mutations Linked to Blood Cancers Rise With Age, Study Shows

Posted 22 Oct 2014 by Drugs.com

WEDNESDAY, Oct. 22, 2014 – Blood cell mutations linked to the blood cancers leukemia and lymphoma increase as people get older, according to a new study. Researchers analyzed blood samples from nearly 3,000 Americans, ages 10 to 90, and found the mutations in less than 1 percent of those ages 40 to 49. By the time people are between 70 and 79, 5 percent will have blood cell mutations, according to the study. For people between 80 and 89, more than 6 percent will be affected, the researchers found. Cell mutations accumulate as people age, and most are harmless, according to the researchers. They said that having these blood cell mutations associated with leukemia and lymphoma doesn't mean a person will develop these blood cancers. In fact, the diseases occur in less than 0.1 percent of elderly Americans, the researchers noted. "But it's quite striking how many people over age 70 have ... Read more

Related support groups: Leukemia, Lymphoma

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Blood Disorders

Related Drug Support Groups

prednisone, methotrexate, cortisone, dexamethasone, Decadron, Revlimid, Imbruvica, Velcade, doxorubicin, view more... ibrutinib, Leukeran, Adriamycin, vinblastine, Deltasone, interferon alfa-2a, Folotyn, Adcetris, lenalidomide, bortezomib, Velban, thiotepa, Sterapred DS, Adrenocot LA, Methotrexate LPF Sodium, Adrenocot, brentuximab, Dexone, Dexpak Taperpak, Liquid Pred, chlorambucil, Sterapred, Trexall, Roferon-A, Ontak, nelarabine, denileukin diftitox, Zydelig, Dexamethasone Intensol, Thioplex, Cortone Acetate, Adriamycin PFS, Beleodaq, Tepadina, Prednicot, Zonacort, LoCort, Zema Pak, Decaject LA, Dalalone, Dalalone DP, Dalalone LA, Decaject, Baycadron, Dexasone, Decadron-LA, Solurex LA, Dexacen-4, Solurex, Hexadrol, Folex PFS, pralatrexate, belinostat, idelalisib, Arranon, De-Sone LA, Dexacort-LA, Medidex LA, Adriamycin RDF, Meticorten, Orasone, Medidex, Dexacorten, Dexasone LA, Dexone LA, Primethasone, Prednicen-M